Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose·2019·Obesity

DOI 10.1002/oby.22344

Cited by (256)

Items 101–200 of 256

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Haoyu Tian, Shuairan Zhang, Ying Liu, Yifan Wu, Dianbao Zhang · 2023 · International Journal of Molecular Sciences
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Xiangchang Zeng, Deliang Huang, Zhibin Zhu, Qingxian Cai, Yang Yang, Hongzhou Lu, Jun Chen · 2025 · Frontiers in Pharmacology
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Randall H. Friedline, Hye Lim Noh, Sujin Suk, Mahaa Albusharif, Sezin Dağdeviren, Suchaorn Saengnipanthkul, Bu Kyung Kim, Allison M. Kim, Lauren H. Kim, LAUREN A. TAUER et al. · 2024 · Nature Communications
Adapting to the cold: A role for endogenous fibroblast growth factor 21 in thermoregulation?
Klein Hazebroek, Marlou, Keipert, Susanne · 2020 · Frontiers in Endocrinology
Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications
Hye‐Yoon Jeon, Ah-Jun Lee, Kwon‐Soo Ha · 2022 · BioChip Journal
Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity
Hajnalka Lőrincz, Sándor Somodi, Balázs Ratku, Mariann Harangi, György Paragh · 2023 · Metabolites
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
Grazia Pennisi, Ciro Celsa, Federica Spatola, Marcello Dallio, Alessandro Federico, Salvatore Petta · 2019 · International Journal of Environmental Research and Public Health
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Emily E. Brown, Theresa Hydes, A. Hamid, Daniel James Cuthbertson · 2021 · Clinical Therapeutics
Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine
Han Fang, Kirsten P. Stone, Laura A. Forney, Desiree Wanders, Thomas W. Gettys · 2021 · Frontiers in Endocrinology
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Yao Zhang, Yibing Wang, Junli Liu · 2022 · Genes & Diseases
Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)
Tobias Puengel, Frank Tacke · 2023 · Expert Opinion on Investigational Drugs
Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
Maria Paula Carbonetti, Fernanda Almeida‐Oliveira, David Majerowicz · 2023 · Archives of Endocrinology and Metabolism
Control of Adipose Cell Browning and Its Therapeutic Potential
Fernando Lizcano, Felipe Arroyave · 2020 · Metabolites
Estrogen-Wnt signaling cascade regulates expression of hepatic fibroblast growth factor 21
Yasaman Badakhshi, Weijuan Shao, Dinghui Liu, Lili Tian, Juan Pang, Jianqiu Gu, Jim Hu, Tianru Jin · 2021 · American Journal of Physiology-Endocrinology and Metabolism
Advances in Biological Functions and Clinical Studies of FGF21
Wei Jye Lin, Tianlei Zhang, Yiyang Zhou, Jinyu Zheng, Zhenlang Lin · 2021 · Diabetes Metabolic Syndrome and Obesity
Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
Matthias Ocker · 2020 · World Journal of Gastroenterology
Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
Yi Luo, Benjamin E. Decato, Edgar D. Charles, Diane E. Shevell, Colleen A. McNaney, Petia A. Shipkova, Abraham Apfel, Giridhar Tirucherai, Arun Jayant Sanyal · 2021 · JHEP Reports
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Ye Ma, Mingjian Zhao, Jifeng Liu, Jun Duan · 2025 · Biomolecules
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?
Qin-Ying She, Jing‐Fu Bao, Hui-Zhen Wang, Huixin Liang, Wentao Huang, Jing Wu, Yi-Wen Zhong, Hanxin Ling, Aiqing Li, Shu-Lan Qin · 2022 · Metabolism
Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans
Julie Mie Jacobsen, Natalia Petersen, Lola Torz, Marina Kjærgaard Gerstenberg, Kent Pedersen, Søren Østergaard, Birgitte Schjellerup Wulff, Birgitte Andersen, Kirsten Raun, Berit Østergaard Christoffersen et al. · 2024 · Cell Reports
Anti-diabetic drugs and NASH: from current options to promising perspectives
Sarra Smati, Clémence M. Canivet, Jérôme Boursier, Bertrand Cariou · 2021 · Expert Opinion on Investigational Drugs
Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats
Erik J. Tillman, William J. Brock, Tim Rolph · 2021 · British Journal of Pharmacology
Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling
Sara Stanić, Kristina Bardová, Petra Janovská, Martin Rossmeisl, Ján Kopecký, Petr Zouhar · 2024 · Biochemical Pharmacology
Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass
Jiun‐Yu Guo, Hsin-Hung Chen, Wei‐Jei Lee, Shuchun Chen, Shou‐Dong Lee, Chih‐Yen Chen · 2022 · Nutrients
Metabolic Factors Determining the Susceptibility to Weight Gain: Current Evidence
Tim Hollstein, Paolo Piaggi · 2020 · Current Obesity Reports
Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity
Emir Tas, Shasha Bai, Xiawei Ou, Kelly E. Mercer, Haixia Lin, Kori Mansfield, Robert F. Buchmann, Eva C. Diaz, Jon David Oden, Elisabet Børsheim et al. · 2020 · Frontiers in Endocrinology
Current understanding and controversies on the clinical implications of fibroblast growth factor 21
Yasaman Badakhshi, Tianru Jin · 2020 · Critical Reviews in Clinical Laboratory Sciences
Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats
Yukiomi Nakade, Rena Kitano, Kazumasa Sakamoto, Satoshi Kimoto, Taeko Yamauchi, Tadahisa Inoue, Yuji Kobayashi, Tomohiko Ohashi, Yoshio Sumida, Kiyoaki Ito et al. · 2021 · PLoS ONE
Emerging roles of fibroblast growth factor 21 in critical disease
Yan Fang, Yuan Li, Fan Yang, Guicheng Wu, Xiaobo Jiang · 2022 · Frontiers in Cardiovascular Medicine
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Rong Xu, Difei Lian, Yan Xie, Zhilei Chen, Yan Wang, Lin Mu, Yuan Wang, Baoyu Zhang · 2023 · Frontiers in Bioscience-Landmark
Spermidine activates adipose tissue thermogenesis through autophagy and fibroblast growth factor 21
Yinhua Ni, Liujie Zheng, Liqian Zhang, Jiamin Li, Yuxiang Pan, Haimei Du, Zhaorong Wang, Zhengwei Fu · 2024 · The Journal of Nutritional Biochemistry
Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity
Yingnan Liang, Qi Chen, Yue Chang, Junsong Han, Jiaxin Yan, Zhenjie Chen, Jingwei Zhou · 2024 · Frontiers in Immunology
Metabolic dysfunction–associated steatotic liver disease, hypertriglyceridaemia, and cardiovascular risk
Gurevitz, Chen, Rosenson, Robert S · 2024 · European Journal of Preventive Cardiology
Novel targeted therapies for the management of liver fibrosis
Juan Pablo Trivella, Paul B. Martin, Andres F. Carrion · 2020 · Expert Opinion on Emerging Drugs
Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic
Sung In Lim · 2019 · Drug Discovery Today
What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline
Karl Sebastian Johansson, David Peick Sonne, Filip Krag Knop, Mikkel Christensen · 2020 · Expert Opinion on Drug Discovery
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Zara Siu Wa Chui, Ya-Qian Xue, Ai-Min Xu · 2024 · Medical Review
Serum β-Klotho concentrations are increased in women with polycystic ovary syndrome
Sylwia Bednarska, Jolanta Fryczak, Agnieszka Siejka · 2020 · Cytokine
FGF21 and its underlying adipose tissue-liver axis inform cardiometabolic burden and improvement in obesity after metabolic surgery
Marie Patt, Isabel Karkossa, Laura Krieg, Lucas Massier, Kassem Makki, Shirin Tabei, Thomas Karlas, Arne Dietrich, Martin T. Gericke, Michael Stümvoll et al. · 2024 · EBioMedicine
New drug therapies for metabolic dysfunction-associated steatohepatitis
John Y.L. Chiang · 2025 · Liver Research
A Critical Assessment of Fasting to Promote Metabolic Health and Longevity
Pouneh K. Fazeli, Matthew L. Steinhauser · 2025 · Endocrine Reviews
Recent advances in the expanding genetic code
Michael L. Pigula, Peter G. Schultz · 2024 · Current Opinion in Chemical Biology
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Brian Finan, Sebastian Demian Parlee, Bin S. Yang · 2020 · Molecular Metabolism
Resting energy metabolism and sweet taste preference during the menstrual cycle in healthy women
Lorena Malo‐Vintimilla, Carolina A. Aguirre, Angie Vergara, Rodrigo Fernández‐Verdejo, José Eduardo Galgani · 2023 · British Journal Of Nutrition
Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Michael M. Richter, Ida M. Kemp, Sara Heebøll, Marie Winther‐Sørensen, Sasha A. S. Kjeldsen, Nicole Jacqueline Jensen, Janus Damm Nybing, Frederik Hvid Linden, Erik Høgh‐Schmidt, Mikael Boesen et al. · 2024 · Metabolism
Fibroblast growth factor 21
Guillaume J Trusz · 2024 · Differentiation
Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients
Adrian Theophil Billeter, Katharina M. Scheurlen, Barbara Israel, Beate Katharina Straub, Peter Schirmacher, Stefan Kopf, Peter P. Nawroth, Beat Peter Müller-Stich · 2022 · Annals of Surgery
Exploring endocrine FGFs - structures, functions and biomedical applications
Phuc Phan · 2024 · International Journal of Biochemistry and Molecular Biology
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Reeju Amatya, Dong-Hee Lee, Kyoung Ah Min, Meong Cheol Shin · 2023 · Pharmaceutics
Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys
Kary E. Thompson, Martin Guillot, Michael J. Graziano, Raja S. Mangipudy, Kristina D. Chadwick · 2021 · Toxicology and Applied Pharmacology
Role of circulating molecules in age-related cardiovascular and metabolic disorders
Yung‐Ting Hsiao, Ippei Shimizu, Yohko Yoshida, Tohru Minamino · 2022 · Inflammation and Regeneration
Inhibition of AXL receptor tyrosine kinase enhances brown adipose tissue functionality in mice
Vissarion Efthymiou, Lianggong Ding, Miroslav Baláž, Wenfei Sun, Lucia Balážová, Leon G. Straub, Hua Dong, Eric Simon, Adhideb Ghosh, Aliki Perdikari et al. · 2023 · Nature Communications
The role of nonmyocardial cells in the development of diabetic cardiomyopathy and the protective effects of FGF21: a current understanding
Tianyi Zhang, Donghui Jiang, Xiao Zhang, Ligang Chen, Jun Jiang, Chunxiang Zhang, Shengbiao Li, Qiuhong Li · 2024 · Cell Communication and Signaling
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao CHEN, Yang Zhou, Haiping Hao, Jing XIONG · 2024 · Chinese Journal of Natural Medicines
Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk
Flavien Berthou, Cyril Sobolewski, Daniel Abegg, Margot Fournier, Christine Maeder, Dobrochna Dolicka, Marta Correia de Sousa, Alexander Adibekian, Michelangelo Foti · 2022 · International Journal of Molecular Sciences
Effect of a 6-Week Carbohydrate-Reduced High-Protein Diet on Levels of FGF21 and GDF15 in People With Type 2 Diabetes
Michael M. Richter, Mads Norvin Thomsen, Mads Juul Skytte, Sasha A. S. Kjeldsen, Amirsalar Samkani, Jan Frystyk, Faidon Magkos, Jens Juul Holst, Sten Madsbad, Thure Krarup et al. · 2024 · Journal of the Endocrine Society
White adipose tissue in type 2 diabetes and the effect of antidiabetic drugs
Yixuan Zhao, Rensong Yue · 2025 · Diabetology & Metabolic Syndrome
Deficiency of Cathelicidin Attenuates High-Fat Diet Plus Alcohol-Induced Liver Injury through FGF21/Adiponectin Regulation
Fengyuan Li, Jenny Chen, Yunhuan Liu, Zelin Gu, Mengwei Jiang, Lihua Zhang, Shaoyu Chen, Zhongbin Deng, Craig James McClain, Wenke Feng · 2021 · Cells
The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise
Ji Ye Lim, Eunju Kim · 2023 · Metabolites
Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Kyeongjin Kim, Kook Hwan Kim · 2020 · International Journal of Molecular Sciences
Hepato-cardiac interorgan communication controls cardiac hypertrophy via combined endocrine-autocrine FGF21 signaling
Sobuj Mia, Georgios Siokatas, Rafailia Sidiropoulou, Matthew Hoffman, Konstantinos Fragkiadakis, Eftychia Markopoulou, Mahmoud Elesawy, Rajika Roy, Scott Blair, Yasuhide Kuwabara et al. · 2025 · Cell Reports Medicine
Endocrine FGFs and their signaling in the brain: Relevance for energy homeostasis
Lucas Zangerolamo, Marina Uchôa Wall Barbosa De Carvalho, Licio Augusto Velloso, Helena C.L. Barbosa · 2023 · European Journal of Pharmacology
A publication-wide association study (PWAS), historical language models to prioritise novel therapeutic drug targets
David Narganes-Carlón, Daniel J Crowther, Ewan R. Pearson · 2023 · Scientific Reports
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Kristian Sass‐Ørum, Tina M. Tagmose, Jørgen Olsen, Annika Sjölander, Per‐Olof Wahlund, Dan Han, Andreas Vegge, Steffen Reedtz‐Runge, Zhe Wang, Xiang Gao et al. · 2024 · Journal of Medicinal Chemistry
The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review
Cristina Elena Negroiu, Iulia Tudorașcu, Maria Cristina Beznă, Adrian Ungureanu, Sorina Octavia Honţaru, Suzana Dănoiu · 2024 · Romanian Journal of Morphology and Embryology
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Chrysoula Boutari, Achilleas Triantafyllou, Lavrentis Papalavrentios, Ioannis Goulis, Emmanouil Sinakos · 2025 · Current Pharmaceutical Design
Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
Chengyuan Liang, Juan Li, Bin Tian, Lei Tian, Yuzhi Liu, Jingyi Li, Liang Xin, Jun Wang, Chao Fu, Zhenfeng Shi et al. · 2021 · Biomedicine & Pharmacotherapy
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Evangelos K. Oikonomou, Maria Xenou, George Ε. Zakynthinos, Paraskevas Tsaplaris, Stamatios Lampsas, Evanthia Bletsa, Ioannis Gialamas, Konstantinos I. Kalogeras, Athina Goliopoulou, Maria Ioanna Gounaridi et al. · 2023 · Current Pharmaceutical Design
Research progress on the role of FGF21 in insulin resistance
Haixin Zhang, Rongyu Zhu, Quanhao Sun, Likun Du · 2025 · Frontiers in Endocrinology
Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
Margery A. Connelly, Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui, Arun Jayant Sanyal · 2020 · Alimentary Pharmacology & Therapeutics
Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans
Thomas P. J. Solomon, Steven Carter, Jacob M. Haus, Kristian Karstoft, Stephanie von Holstein‐Rathlou, Mette S. Nielsen, Matthew Paul Gillum · 2022 · PeerJ
Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity
Daejin Kim, Jong‐Soo Lee, InHwan Bae, Minyoung Kim, Youngho Huh, Jaehyuk Choi, Sungmin Bae, In Young Choi, Ha Hyung Kim, Dae Kyong Kim · 2020 · Biologicals
Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next
Tianru Jin · 2022 · Medical Review
Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta‐Analysis of Randomized Controlled Trials
Zizheng Nie, Jiaoyang Xu, Yingying Liu, Qinglong Cao, Xinyi Qiu, Yiping Su, Shufen Han · 2025 · International Journal of Endocrinology
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21
Jia Bao Pan, Sebastian Demian Parlee, Florence M. Brunel, Pengyun Li, Wei Lu, Diego Pérez–Tilve, Fa Liu, Brian Finan, Alexei Kharitonenkov, Richard D. DiMarchi · 2020 · ACS Pharmacology & Translational Science
Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations
Maria I. Stamou, Crystal J Chiu, Shreya V. Jadhav, Vanessa Ferreira Lopes, Kathryn B. Salnikov, Lacey Plummer, Margaret Flynn Lippincott, Hang Lee, Stephanie Beth Seminara, Ravikumar Balasubramanian · 2024 · Journal of the Endocrine Society
Acute Deletion of the FOXO1-dependent Hepatokine FGF21 Does not Alter Basal Glucose Homeostasis or Lipolysis in Mice
Jaimarie Sostre‐Colón, Matthew J. Gavin, Dominic Santoleri, Paul M. Titchenell · 2022 · Endocrinology
Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction?
Niki Katsiki, Christos Socrates Mantzoros · 2019 · Metabolism
Effects of beta-conglycinin intake on circulating FGF21 levels and brown adipose tissue activity in Japanese young men: a single intake study and a randomized controlled trial
Hirokazu Taniguchi, Keigo Shimizu, Sayori Wada, Shinsuke Nirengi, Haruki Kataoka, Akane Higashi · 2020 · Journal of PHYSIOLOGICAL ANTHROPOLOGY
Fibroblast Growth Factor 21 Protects Against Cerebral Ischemia/Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis
Junjie Li, Haiyan Jiang, Wenya Bai, Yuan Yang, Guilin Zhou, Wendong Chen, Jianlin Shao · 2025 · Neuropsychiatric Disease and Treatment
Exercise training enhances myokine release and reduces brain insulin resistance: insights into muscle-CNS metabolic cross-talk
Zahra Samadian, Laya Samadian, Ehsan Arabzadeh · 2025 · Metabolic Brain Disease
Adipocyte Browning: A Promising Avenue in Anti-Obesity Therapy
Young‐An Bae, Hyae Gyeong Cheon · 2026 · International Journal of Molecular Sciences
Roles of FGF21 and irisin in obesity-related diabetes and pancreatic diseases
Ting Xie, Po Sing Leung · 2020 · Journal of Pancreatology
Molecular mechanisms linking adipose tissue browning to reduced cardiovascular risk
Ana Checa-Ros, Luis D’Marco · 2025 · Atherosclerosis
The burn repair molecule? Evaluating FGF-21 in thermal injury – A systematic review
Tobias Niederegger, Thomas Schaschinger, Jule Brandt, Leonard Knoedler, Samuel A. Knoedler, Alen Palackic, Felix J Klimitz, Dorothea Noll, Patrick Most, Julia Ritterhoff et al. · 2025 · Burns
Current Role and Potential of Polymeric Biomaterials in Clinical Obesity Treatment
Rui‐Chian Tang, I‐Hsuan Yang, Feng‐Huei Lin · 2023 · Biomacromolecules
Activation of activator protein-1-fibroblast growth factor 21 signaling attenuates Cisplatin hepatotoxicity
Yue Zhang, Yuan Le, Yue Ji, Shari Yarde, Xiaoxiao Yu, Xingguo Cheng · 2021 · Biochemical Pharmacology
Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis
Haiying Tang, Jiahui Li, Bradley A. Zinker, Stephanie Boehm, Amy S. Mauer, Sandra Rex‐Rabe, Kevin J. Glaser, Matthew P. Fronheiser, Thomas E. Bradstreet, Yasuhiko Nakao et al. · 2022 · Journal of Magnetic Resonance Imaging
Hepatic Hedgehog Signaling Participates in the Crosstalk between Liver and Adipose Tissue in Mice by Regulating FGF21
Fritzi Ott, Christiane Körner, Kim Werner, Martin T. Gericke, Ines Liebscher, Donald Lobsien, Silvia Radrezza, Andrej Shevchenko, Ute Hofmann, Jürgen Kratzsch et al. · 2022 · Cells
Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis
Chih-Ming L. Tseng, Kemal Balic, R. Will Charlton, Maya Margalit, Hank Mansbach, Radojka M. Savić · 2023 · Clinical Pharmacology & Therapeutics
Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease
M.A. Karsdal, Kate Hallsworth, Jadine H. Scragg, Diana Julie Leeming, Ida Falk Villesen, Leah Avery, Laura Haigh, Olivier Govaere, Sarah Wichmann, Guy Taylor et al. · 2023 · Hepatology Communications
Association of serum fibroblast growth factor 21 and urinary glucose excretion in hospitalized patients with type 2 diabetes
Rui Zhang, Xiaoling Cai, Yongrui Du, Liu Liu, Xueyao Han, Wei Liu, Siqian Gong, Xianghai Zhou, Xiangqing Wang, Xin Wen et al. · 2020 · Journal of Diabetes and its Complications
Investigation of the Characteristics of Crimean Congo Hemorrhagic Fever Cases Reported in Afyonkarahisar Province
Derya Korkmaz, Petek Şarlak Konya, Neşe Demirtürk · 2022 · Turkish Journal of Parasitology
Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction
Kaanthi Rama, Vinay Jahagirdar, Arun Jayant Sanyal · 2026 · Drug Design Development and Therapy
Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
Daniel Guldager Kring Rasmussen, Michael K. Hansen, Peder Frederiksen, Yunyun Luo, Martin Pehrsson, Bruce Charles Neal, M.A. Karsdal, Federica Genovese · 2024 · Diabetes Obesity and Metabolism
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Xiaokun Li, Zhiheng Rao, Wenhao Hu, Weiqin Lu, Yongde Luo · 2024 · Obesity Reviews
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
Davide Misceo, Gabriele Mocciaro, Simona D’Amore, Michèle Vacca · 2024 · Nutrition & Metabolism
Is Trimming the Fat Enough? Fibroblast Growth Factor 21 as An Emerging Treatment for Nonalcoholic Fatty Liver Disease
Jody R. Dushay, Michelle Lai · 2019 · Hepatology
Seed- and leaf-based expression of FGF21-transferrin fusion proteins for oral delivery and treatment of non-alcoholic steatohepatitis
Hsuan-Wu Hou, Christopher A. Bishop, Jana Huckauf, Inge Broer, Susanne Klaus, Henrik Nausch, Johannes F. Buyel · 2022 · Frontiers in Plant Science
Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats
Emily J. Brinker, Taylor J. Towns, Rie Watanabe, Xiaolei Ma, Adil Bashir, Robert C. Cole, Xu Wang, Emily C. Graff · 2023 · Frontiers in Veterinary Science